To explore the relationship between high density lipoprotein (HDL) and lower extremities deep venous thrombosis (DVT) in patients undergoing hip arthroplasty.
Methods
A total of 348 patients undergoing hip arthroplasty in our hospital were enrolled, and divided into observation (n = 154, 44.25%) and control (n = 194, 55.75%) groups according to the occurrence of lower extremities DVT. The presence of DVT was assessed 1 day before surgery and routinely every 2 days after surgery. The factors of DVT were analyzed by single factor analysis, multivariate logistic regression analysis, and Pearson correlation.
Results
The age and body mass index in the observation group were significantly higher (p = .045, p = .041, respectively), while HDL-C was significantly lower (p = .032) than the control group. Increase age, high BMI, low apolipoprotein-A1 level and low HDL-C level were risk factors for lower extremities DVT. The mean HDL-C in the observation and control groups was 0.91 ± 0.27 and 1.19 ± 0.37, respectively, the adjusted odds ratio was 1.050; 95% CI 1.010–1.092, p = .014.
Conclusion
Elderly patients with high BMI and low HDL-C level undergoing hip arthroplasty are at risk of lower extremities DVT, and should be paid attention to clinically.
ZhangXLiMWenF, et al.Different impact of high-density lipoprotein-related genetic variants on polypoidal choroidal vasculopathy and neovascular age-related macular degeneration in a Chinese Han population. Exp Eye Res2013; 108: 16–22.
2.
AngeloniEPaneniFLandmesserU, et al.Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting. Eur Heart J2013; 34(46): 3557–3562.
3.
MaJQinJHuJ, et al.Incidence and hematological biomarkers associated with preoperative deep venous thrombosis following foot fractures. Foot Ankle Int2020; 41(12): 1563–1570.
4.
LiuT. Study on specific serum protein of heart and kidney damage in hypertension; High density lipoprotein cholesterol levels are associated with all-cause mortality in patients with cerebral thrombosis. Master Thesis. Beijing, China: Peking Union Medical College. Chinese Academy of Medical Sciences, 2017. (in Chinese).
5.
Estrada-LunaDOrtiz-RodriguezMAMedina-BriseñoL, et al.Current therapies focused on high-density lipoproteins associated with cardiovascular disease. Molecules2018; 23(11): 2730.
6.
OuimetMBarrettTJFisherEA. HDL and reverse cholesterol transport. Circ Res2019; 124(10): 1505–1518.
7.
ZhangQFPengBLiuRM. Vascular protection dysfunction of high-density lipoprotein in patients with diabetic retinopathy. Rec Adv Ophthalmol2018; 38(5): 482–484. (in Chinese).
8.
EichingerSPecheniukNMHronG, et al.High-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation2007; 115(12): 1609–1614.
9.
KimJS. Deep vein thrombosis prophylaxis after total hip arthroplasty in Asian patients. Hip Pelvis2018; 30(4): 197–201.
10.
LeeSYRo duHChungCY, et al.Incidence of deep vein thrombosis after major lower limb orthopedic surgery: analysis of a nationwide claim registry. Yonsei Med J2015; 56(1): 139–145.
11.
KucherN. Clinical practice. Deep-vein thrombosis of the upper extremities. N Engl J Med2011; 364(9): 861–869.
12.
YuXWuYNingR. The deep vein thrombosis of lower limb after total hip arthroplasty: what should we care. BMC Musculoskelet Disord2021; 22: 547.
13.
ThiengwittayapornSBudhiparamaNTanavaleeC, et al.Kang-Il Kim; the Asia-Pacific (AP) region venous thromboembolism (VTE) consensus group. Asia-Pacific venous thromboembolism consensus in knee and hip arthroplasty and hip fracture surgery: Part 3. Pharmacological venous thromboembolism prophylaxis. Knee Surg & Relat Res2021; 33: 24.
14.
KahnSRShivakumarS. What's new in VTE risk and prevention in orthopedic surgery. Res Pract Thromb Haemost2020; 4(3): 366–376.
15.
ChariAKhokharAMurrayD, et al.Venous thromboembolism and its prophylaxis in elective total hip arthroplasty: an international perspective. Hip Int2012; 22(1): 1–8.
16.
ColwellCW. The ACCP guidelines for thromboprophylaxis in total hip and knee arthroplasty. Orthopedics2009; 32(12 Suppl): 67–73.
17.
Tosheska TrajkovskaKTopuzovskaS. High-density lipoprotein metabolism and reverse cholesterol transport: strategies for raising HDL cholesterol. Anatol J Cardiol2017; 18(2): 149–154.
18.
GaoZChenHHuangP, et al.Restropective analysis of clinical risk factors of femoral venous catheter-associated thrombosis in hemodialysis patients. J Clin Nephrol2016; 16(1): 32–35, (in Chinese).
19.
van der StoepMKorporaalSJVan EckM. High-density lipoprotein as a modulator of platelet and coagulation responses. Cardiovasc Res2014; 103(3): 362–371.
20.
Timón-ZapataJLaserna-MendietaEJSáenz-MateosLF, et al.A multicentre analysis of four low-density lipoprotein cholesterol direct assays in samples with extreme high-density lipoprotein cholesterol concentrations. Clin Chim Acta2014; 430: 71–76.
21.
MorelliVMLijferingWMBosMHA, et al.Lipid levels and risk of venous thrombosis: results from the MEGA-study. Eur J Epidemiol2017; 32(8): 669–681.
22.
van der StoepMKorporaalSJVan EckM. High-density lipoprotein as a modulator of platelet and coagulation responses. Cardiovasc Res2014; 103(3): 362–371.
23.
WangBWuLChenJ, et al.Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets. Signal Transduct Target Ther2021; 6(1): 94.
24.
LiuDJiLWangY, et al.Cyclooxygenase-2 expression, prostacyclin production and endothelial protection of high-density lipoprotein. Cardiovasc Hematol Disord Drug Targets2012; 12(2): 98–105.
25.
ErenEYılmazNAydinO, et al.Anticipatory role of high density lipoprotein and endothelial dysfunction: an overview. Open Biochem J2014; 8: 100–106.
26.
Tran-DinhADialloDDelboscS, et al.HDL and endothelial protection. Br J Pharmacol2013; 169(3): 493–511.
27.
KratzerAGiralHLandmesserU. High-density lipoproteins as modulators of endothelial cell functions: alterations in patients with coronary artery disease. Cardiovasc Res2014; 103(3): 350–361.
28.
RobertJOstoEvon EckardsteinA. The endothelium is both a target and a barrier of HDL’s protective functions. Cells2021; 10(5): 1041.
29.
XuBBGouZHZhouL, et al.Low plasma high density lipoprotein-cholesterol level associated with deep vein thrombosis in traumatic fracture patients. J Sichuan Univ (Med Sci Ed). 2019; 50(2): 248–251, (in Chinese).
30.
BudnikIBrillA. Immune Factors in deep vein thrombosis initiation. Trends Immunol2018; 39(8): 610–623.
31.
TrakakiAMarscheG. Current Understanding of the immunomodulatory activities of high-density lipoproteins. Biomedicines2021; 9(6): 587.
32.
SmithJD. Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis. Curr Opin Investig Drugs2010; 11(9): 989–996.
33.
GuanZChenYSongY. Influence of body mass index and age on deep vein thrombosis after total hip and knee arthroplasty. Chin J Repar Reconst Surg2006; 20(6): 611–615, (in Chinese).
